Anticorps Polyclonal de lapin anti-ERCC6L

• Phare
• Validé par KD/KO

ERCC6L Polyclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications

7

N° de cat : 15688-1-AP

Synonymes

ERCC6L, PICH, Tumor antigen BJ HCC 15

---

Galerie de données de validation

• 

  WB analysis using 15688-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human heart using 15688-1-AP

  human heart tissue were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse lung using 15688-1-AP

  mouse lung tissue were subjected to SDS PAGE followed by western blot with 15688-1-AP (ERCC6L antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 15688-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 15688-1-AP (ERCC6L antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 15688-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 15688-1-AP (ERCC6L antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules Jurkat, cellules K-562, cellules U2OS, tissu cardiaque humain, tissu pulmonaire de souris
• Résultats positifs en IHC: tissu de cancer du côlon humain, ; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:6000
• Immunohistochimie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 2 publications below
• WB: See 7 publications below
• IHC: See 2 publications below

Informations sur le produit

15688-1-AP cible ERCC6L dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: ERCC6L Protéine recombinante Ag8223
• Nom complet: excision repair cross-complementing rodent repair deficiency, complementation group 6-like
• Masse moléculaire calculée: 419 aa, 46 kDa, 141 kDa
• Poids moléculaire observé: 180 kDa
• Numéro d’acquisition GenBank: BC008808
• Symbole du gène: ERCC6L
• Identification du gène (NCBI): 54821
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

ERCC6L, also named as Tumor antigen BJ-HCC-15 or PICH, is a 1250 amino acid protein, which contains one helicase ATP-binding domain, one helicase C-terminal domain and two TPR repeats. ERCC6L localizes to kinetochores, inner centromeres and belongs to the SNF2/RAD54 helicase family. ERCC6L as a DNA helicase that acts as an essential component of the spindle assembly checkpoint. The calculated molecular weight of ERCC6L is 140 kDa, but the phosphorylated modification of molecular weight of ERCC6L is about 180kDa.

Publications

Species	Application	Title
human	WB	Eur J Med Res; Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells; Authors - Chao Li
human,mouse	WB	J Ethnopharmacol; Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1.; Authors - Ma-Li Zu
human	WB	Oncol Rep; Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.; Authors - Xiaoyue Huang
human	WB	BMC Cancer; ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.; Authors - Han Chen ; KD Validated
human	WB,IHC	Oncol Lett; ERCC6L promotes cell growth and invasion in human colorectal cancer.; Authors - Yang Xie ; KD Validated
human	WB,IHC	Cancer Res; PICH activates Cyclin A1 transcription to drive S-phase progression and chemoresistance in gastric cancer; Authors - Huili Ye